BGV appoints Elena Ritsou as Venture Partner and Andree Blaukat as Senior Advisor Amsterdam, The Netherlands - 8 November 2022 - BioGeneration Ventures ("BGV"), a leading early-stage
Merck KGaA signs deal with Artios Pharma potentially worth up to $860m
Three-year collaboration agreement will seek to develop a range of therapeutic candidates
Merck KGaA has signed a strategic collaboration agreement with Artios Pharma to develop precision cancer medicines targeting DNA damage response pathways.
As part of the three-year strategic research collaboration agreement, the companies will utilise Artios’ nuclease targeting discovery platform to identify multiple targets for precision cancer drug candidates.
Under the terms of the agreement, Merck KGaA will pay Artios $30m upfront, as well as near-term payments. Artios will also be eligible to receive up to $860m per target if Merck KGaA chooses to exercise the option to develop and commercialise a candidate.